CAMBRIDGE, Mass.--(BUSINESS WIRE)--Fidelity Biosciences announced today that it is joining with Devonshire Investors’ technology venture capital fund to become F-Prime Capital. F-Prime Capital will create a new, unified name for the venture capital funds of FMR LLC, the parent company of Fidelity Investments, and continue its 40-year history as an active global investor in life sciences, healthcare and technology.
“Throughout the firm’s history, our scale and scope have grown with the addition of new venture funds, domain expertise and global reach,” said Stephen Knight, managing partner for the firm. “While our venture teams retain a strong cultural bond with Fidelity Investments, we are introducing a new name to both reflect our increased market presence and to clarify our mission as a venture capital investor in private companies apart from Fidelity Investments' mutual fund business.”
Over the past 15 years, the F-Prime Capital teams have invested in more than 89 companies in five countries across five funds. The teams have focused on innovative early-stage companies addressing significant needs in the technology and life sciences sectors.
“We will carry on our mission of partnering with leading entrepreneurs and top academics to build great companies and to invent and deliver real solutions to some of the world’s biggest challenges in healthcare and technology,” said Knight. “We look forward to continuing this work under our new name, F-Prime Capital.”
About F-Prime Capital Partners
F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology.
